



# Artisan Mid Cap Fund

MONTHLY  
Commentary

Investor Class: ARTMX | Advisor Class: APDMX As of 30 April 2019

## Commentary

Markets continued their steady rise in April, with US stocks leading the way, followed by foreign developed markets and then emerging. Investors seemed pleased with the combination of steady economic data, solid corporate earnings and growing signs of trade resolution between the US and China. At the sector level, financials and technology were among the leaders, while health care was the primary laggard amid amplifying political rhetoric, particularly in the US.

Our portfolio is outperforming the Russell Midcap® and Russell Midcap® Growth Indices QTD. Among our top contributors are Cree and Progressive. Cree, which has a dominant position in the silicon carbide (SiC) business, is capitalizing on expanded manufacturing capacity along with easing trade-related sentiment to drive accelerating growth. In April, the FTC granted antitrust clearance for Ideal Industries' purchase of Cree's lighting business—a divestiture of a legacy business which we anticipate will allow Cree to focus more narrowly on its rapidly growing SiC business in the period ahead.

Progressive is one of the leading insurance companies in the US. We have held Progressive as its low-cost structure, superior market segmentation data and entry into the homeowners' insurance market have allowed it to grow its market share over time. The company has executed well, increasing net premiums written while improving profitability. We maintain our conviction in the growth runway ahead as Progressive continues investing in new technologies—such as in-car monitoring and machine learning—to better segment its customers based on risk profiles.

Among our bottom contributors are Boston Scientific and Edwards Lifesciences. Shares of Boston Scientific, a leading developer and manufacturer of minimally invasive medical devices, were pressured by a combination of headwinds that slowed results more than anticipated. Though we believe these challenges likely prove short term, we modestly pared our exposure as heightened political rhetoric contributes to some uncertainty around the near-term outlook.

Edwards Lifesciences is the leader in transcatheter aortic valve replacements (TAVR)—one of the fastest growing, large medical device markets globally. In March, the company released results from its landmark clinical trial studying its SAPIEN 3 heart valve in lower risk aortic stenosis patients. Data showed impressive superiority for Edwards' valve compared to open-heart surgery. Though shares have consolidated recent gains, we maintain our conviction in the opportunity ahead—though we have pared our exposure in accordance with our valuation discipline.

Our process is focused on identifying franchises exposed to accelerating profit cycles with reasonable valuations. It is our belief that owning companies with these characteristics should lead to outperformance over full market cycles. We will continue to adhere to this approach, regardless of the macro backdrop and how it evolves in the period ahead.

## Portfolio Details

	ARTMX	APDMX
Net Asset Value (NAV)	\$36.69	\$36.98
Inception	27 Jun 1997	1 Apr 2015
Expense Ratios		
Annual Report 30 Sep 2018	1.18%	1.04%
Prospectus 30 Sep 2018 <sup>1</sup>	1.18%	1.05%

<sup>1</sup>See prospectus for further details.

## Top 10 Holdings (% of total portfolio)

Global Payments Inc (Information Technology)	5.4
Atlassian Corp PLC (Information Technology)	4.0
Veeva Systems Inc (Health Care)	3.8
The Progressive Corp (Financials)	3.6
IHS Markit Ltd (Industrials)	3.6
Worldpay Inc (Information Technology)	3.3
Tableau Software Inc (Information Technology)	2.8
Boston Scientific Corp (Health Care)	2.8
Roper Technologies Inc (Industrials)	2.7
Harris Corp (Industrials)	2.5
<b>TOTAL</b>	<b>34.4%</b>

Source: Artisan Partners/FactSet (GICS).

## Sector Diversification (% of total portfolio equities)

	Fund	RMCG <sup>1</sup>
Communication Services	3.9	3.9
Consumer Discretionary	12.2	16.2
Consumer Staples	0.0	3.0
Energy	0.0	1.4
Financials	8.0	6.7
Health Care	23.4	13.5
Industrials	15.7	15.8
Information Technology	35.7	33.7
Materials	1.0	3.5
Real Estate	0.0	2.2
Utilities	0.0	0.0
<b>TOTAL</b>	<b>100.0%</b>	<b>100.0%</b>

Source: Artisan Partners/FactSet (GICS)/Russell. Cash and cash equivalents represented 3.1% of the total portfolio. <sup>1</sup>Russell Midcap® Growth Index.

## Investment Results (%)

As of 30 April 2019	Average Annual Total Returns							
	MTD	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception
Investor Class: ARTMX	4.59	4.59	27.22	17.43	15.04	10.47	15.61	13.36
Advisor Class: APDMX	4.58	4.58	27.30	17.56	15.17	10.59	15.67	13.38
Russell Midcap® Growth Index	4.50	4.50	25.00	17.64	16.78	12.20	16.56	8.99
Russell Midcap® Index	3.81	3.81	20.97	10.69	12.82	9.75	15.65	9.82
As of 31 March 2019								
Investor Class: ARTMX	0.92	21.64	21.64	12.30	13.87	8.00	16.72	13.18
Advisor Class: APDMX	0.91	21.72	21.72	12.43	14.01	8.11	16.79	13.21
Russell Midcap® Growth Index	1.35	19.62	19.62	11.51	15.06	10.89	17.60	8.80
Russell Midcap® Index	0.86	16.54	16.54	6.47	11.82	8.81	16.88	9.67

Source: Artisan Partners/Russell. Returns for periods less than one year are not annualized. Class inception: Investor (27 June 1997); Advisor (1 April 2015). For the period prior to inception, Advisor Class performance is the Investor Class's return for that period ("Linked Performance"). Linked Performance has not been restated to reflect expenses of the Advisor Class and the share class's returns during that period would be different if such expenses were reflected.

Past performance does not guarantee and is not a reliable indicator of future results. Investment returns and principal values will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than that shown. Call 800.344.1770 for current to most recent month-end performance.

## Market Cap Distribution (% of total portfolio equities)

\$ in billions	Fund	RMCG <sup>1</sup>
22.0+	44.5	33.9
16.0–22.0	11.4	17.4
11.3–16.0	12.1	17.4
7.2–11.3	18.7	18.0
0–7.2	13.3	13.2
<b>TOTAL</b>	<b>100.0%</b>	<b>100.0%</b>

Source: Artisan Partners/FactSet/Russell. <sup>1</sup>Russell Midcap<sup>®</sup> Growth Index.

## Team Leadership (Pictured left to right)



Portfolio Managers	Years of Investment Experience
Matthew H. Kamm, CFA (Lead)	19
James D. Hamel, CFA	22
Craigh A. Cepukenas, CFA	30
Jason L. White, CFA	19

Carefully consider the Fund's investment objective, risks and charges and expenses. This and other important information is contained in the Fund's prospectus and summary prospectus, which can be obtained by calling 800.344.1770. Read carefully before investing.

International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period.

Russell Midcap<sup>®</sup> Growth Index measures the performance of US mid-cap companies with higher price/book ratios and forecasted growth values. Russell Midcap<sup>®</sup> Index measures the performance of roughly 800 US mid-cap companies. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

For the purpose of determining the Fund's holdings, securities of the same issuer are aggregated to determine the weight in the Fund. The discussion of portfolio holdings does not constitute a recommendation of any individual security. These holdings comprise the following percentages of the Fund's total net assets as of 30 Apr 2019: Cree Inc 2.2%; Edwards Lifesciences Corp 1.0%. Securities named in the Commentary, but not listed as a Top Ten Holding or not listed here are not held in the Fund as of the date of this report. The portfolio managers' views and portfolio holdings are subject to change and the Fund disclaims any obligation to advise investors of such changes.

Unless otherwise indicated, all information in this report includes all classes of shares, except performance and expense ratio information, and is as of the date shown in the upper right hand corner. Totals may not sum due to rounding.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein.

The Global Industry Classification Standard (GICS<sup>®</sup>) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

Frank Russell Company ("Russell") is the source and owner of the trademarks, service marks and copyrights related to the Russell Indexes. Russell<sup>®</sup> is a trademark of Frank Russell Company. Neither Russell nor its licensors accept any liability for any errors or omissions in the Russell Indexes and/or Russell ratings or underlying data and no party may rely on any Russell Indexes and/or Russell ratings and/or underlying data contained in this communication. No further distribution of Russell Data is permitted without Russell's express written consent. Russell does not promote, sponsor or endorse the content of this communication.

Sector exposure percentages reflect sector designations as currently classified by GICS.

Our capital allocation process is designed to build position size according to our conviction. Portfolio holdings develop through three stages: Garden<sup>SM</sup>, Crop<sup>SM</sup> and Harvest<sup>SM</sup>. Garden<sup>SM</sup> investments are situations where we believe we are right, but there is not clear evidence that the profit cycle has taken hold, so positions are small. Crop<sup>SM</sup> investments are holdings where we have gained conviction in the company's profit cycle, so positions are larger. Harvest<sup>SM</sup> investments are holdings that have exceeded our estimate of intrinsic value or holdings where there is a deceleration in the company's profit cycle. Harvest<sup>SM</sup> investments are generally being reduced or sold from the portfolios.

Artisan Partners Funds offered through Artisan Partners Distributors LLC (APDLLC), member FINRA. APDLLC is a wholly owned broker/dealer subsidiary of Artisan Partners Holdings LP. Artisan Partners Limited Partnership, an investment advisory firm and adviser to Artisan Partners Funds, is wholly owned by Artisan Partners Holdings LP.

© 2019 Artisan Partners. All rights reserved.

5/3/2019 A19629L\_vR